CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
– Co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital – – Proceeds to accelerate clinical programs across bladder cancer including in the first-line setting, positioning CG Oncology as the leading urologic oncology company – – Brian Liu, M.D., … [Read more…]
